アレルギー性鼻炎治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 12
1.1 List of Tables 18
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.2 Symptoms 27
3.3 Classification 28
3.3.1 Seasonal and Perennial AR 28
3.3.2 ARIA Classification of AR 28
3.4 Diagnosis 29
3.5 Quality of Life 31
4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 33
4.2.1 A family history of AR is a strong predictor for AR in children and adults 34
4.2.2 Exposure to allergens in the environment increases the risk for AR 35
4.2.3 Urban living elevates the risk for AR 35
4.2.4 Comorbidities 36
4.3 Global and Historical Trends 38
4.3.1 US 38
4.3.2 5EU 39
4.3.3 Japan 40
4.4 Forecast Methodology 41
4.4.1 Sources Used 43
4.4.2 Sources Not Used 46
4.4.3 Forecast Assumptions and Methods 46
4.5 Epidemiological Forecast for AR (2013-2023) 49
4.5.1 Total Prevalent Cases of AR 49
4.5.2 Age-Specific Total Prevalent Cases of AR 51
4.5.3 Sex-Specific Total Prevalent Cases of AR 53
4.5.4 Age-Standardized Total Prevalence of AR 55
4.5.5 Distribution of Total Prevalent Cases of AR by Severity 57
4.5.6 Distribution of Total Prevalent Cases of AR by Type 58
4.5.7 Distribution of Total Prevalent Cases of AR Sensitized to Specific Allergens 59
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 60
4.6.3 Strengths of the Analysis 61
5 Disease Management 62
5.1 Diagnosis and Treatment Overview 62
5.1.1 Diagnosis 62
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 63
5.1.3 Clinical Practice 66
5.2 US 75
5.3 France 78
5.4 Germany 80
5.5 Italy 84
5.6 Spain 86
5.7 UK 88
5.8 Japan 90
6 Competitive Assessment 93
6.1 Overview 93
6.2 Oral H1 Antihistamines 97
6.2.1 Overview 97
6.2.2 Efficacy 106
6.2.3 Safety 107
6.2.4 SWOT Analysis 109
6.2.5 Forecast 110
6.3 Intranasal Antihistamines 110
6.4 Intranasal Corticosteroids 113
6.4.1 Overview 113
6.4.2 Efficacy 120
6.4.3 Safety 122
6.4.4 SWOT Analysis 123
6.4.5 Forecast 124
6.5 Combination Intranasal Corticosteroids/Antihistamines 124
6.5.1 Dymista 124
6.6 Decongestants 133
6.6.1 Overview 133
6.7 Intranasal Anticholinergics 136
6.7.1 Overview 136
6.8 Leukotriene Receptor Antagonists 137
6.8.1 Overview 137
6.9 Cromones 140
6.9.1 Overview 140
6.10 Thromboxane A2 Receptor Antagonists 141
6.10.1 Overview 141
6.11 TH2 Cytokine Inhibitors 142
6.11.1 Overview 142
7 Unmet Need and Opportunity 143
7.1 Overview 143
7.2 Pharmacist Education 145
7.2.1 Unmet Need 145
7.2.2 Gap Analysis 147
7.2.3 Opportunity 148
7.3 Patient Compliance With Intranasal Corticosteroids and Antihistamines 150
7.3.1 Unmet Need 150
7.3.2 Gap Analysis 151
7.3.3 Opportunity 153
7.4 More Convenient and More Patient-Friendly Immunotherapies 156
7.4.1 Unmet Need 156
7.4.2 Gap Analysis 157
7.4.3 Opportunity 159
7.5 Primary Care Physician Education 160
7.5.1 Unmet Need 160
7.5.2 Gap Analysis 162
7.5.3 Opportunity 163
8 Pipeline Assessment 165
8.1 Promising Drugs in Clinical Development 166
8.1.1 S-555739 166
8.1.2 HP-3060 172
9 Current and Future Players 177
9.1 Overview 177
9.2 Trends in Corporate Strategy 179
9.3 Major Companies 180
9.3.1 Merck & Co. 180
9.3.2 GlaxoSmithKline 184
9.3.3 Sumitomo Dainippon Pharma 186
9.3.4 Sanofi 188
9.3.5 Teva 191
9.3.6 Meda AB 192
10 Market Outlook 195
10.1 Global Markets 195
10.1.1 Forecast 195
10.1.2 Drivers and Barriers – Global Issues 200
10.2 United States 205
10.2.1 Forecast 205
10.2.2 Key Events 210
10.2.3 Drivers and Barriers 210
10.3 5EU 212
10.3.1 Forecast 212
10.3.2 Key Events 217
10.3.3 Drivers and Barriers 217
10.4 Japan 225
10.4.1 Forecast 225
10.4.2 Key Events 230
10.4.3 Drivers and Barriers 230
11 Appendix 234
11.1 Bibliography 234
11.2 Abbreviations 247
11.3 Methodology 252
11.4 Forecasting Methodology 252
11.4.1 Pediatric Allergic Rhinitis Population 252
11.4.2 Diagnosed AR Patients 258
11.4.3 Percentage of Drug-Treated Patients 258
11.4.4 Drugs Included in Each Therapeutic Class 258
11.4.5 Launch and Patent Expiry Dates 261
11.4.6 1General Pricing Assumptions 262
11.4.7 Individual Drug Assumptions 263
11.4.8 Generic Erosion 272
11.4.9 Pricing of Pipeline Agents 272
11.5 Physicians and Specialists Included in This Study 273
11.6 About the Authors 277
11.6.1 Analyst 277
11.6.2 Therapy Area Director 277
11.6.3 Epidemiologist 278
11.6.4 Global Head of Healthcare 278
11.7 About GlobalData 279
11.8 Disclaimer 279